Cytora, a biopharmaceutical firm, announced positive outcomes from its Phase 1/2a trial concerning hOMSC200, a stem cell therapy for diabetic foot ulcers.
The study indicated that the treatment, derived from oral mucosa stem cells, is safe and did not trigger immune responses in patients.
Furthermore, hOMSC200 demonstrated superior effectiveness in healing these chronic wounds compared to the standard treatment.
These encouraging results pave the way for Cytora to seek regulatory approval for larger Phase 2 trials in 2026.
Diabetic foot ulcers are a significant complication of diabetes, often leading to severe consequences and high treatment costs, highlighting the need for improved therapies.
Cytora’s unique stem cell technology, based on readily available and potent oral mucosa stem cells, presents a promising “off-the-shelf” solution for this challenging condition and potentially other diseases.
Listen to our latest podcast episode for more details:
More info: https://www.cytorastem.com
